Thursday, January 09, 2020 8:03:57 AM
Stocks mentioned: FOMX
REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 9, 2020 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced that its novel AMZEEQ™ (minocycline) topical foam, 4% will be available on January 13, 2020 by prescription for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Approved by the U.S. Food and Drug Administration (FDA) in October 2019, AMZEEQ is the first topical minocycline to be FDA approved for any condition and represents the company's first commercial product launch. This new once-daily therapy will be available in retail, community and specialty pharmacies nationwide.
The Company also announced that the annual list price of AMZEEQ will be $485 per 30-gram canister. This is a lower price per unit than that of current brand leaders in the acne prescription market, setting AMZEEQ apart in terms of its pricing approach.
Foamix employed a team of experts to develop the Company's approach for engaging commercial insurers to offer the broadest possible access to AMZEEQ for patients and healthcare professionals. The Company will provide copay card assistance for eligible commercially insured patients. An electronic benefit verification tool is also available through the product website, AMZEEQ.com, to assist healthcare professionals and patients to understand their likely insurance coverage and out-of-pocket costs.
Foamix has also developed a multi-channel tactical marketing plan to reach customers, including a sales force deployment to more than 6,000 acne-treating providers with product samples. Foamix will broadcast a promotional speaker program for relevant health care professionals ("HCPs") nationally on February 13, 2020 to share AMZEEQ product and prescribing information. In addition, Foamix is deploying a broad range of digital consumer outreach tactics, including product information and a unique unboxing-style "how to use" video designed to be easily understood by an adolescent patient population and based on AMZEEQ's instructions for use.
"Moderate to severe acne is a challenging and burdensome condition of many sufferers. AMZEEQ is now positioned to become an important tool in managing this condition," said David Domzalski, Chief Executive Officer of Foamix. "We recognize that providers and acne sufferers have been seeking alternatives in acne treatment, and I'm very proud of the program we've designed to provide broad awareness and availability of AMZEEQ for physicians and patients."
Minocycline, a broad-spectrum antibiotic known for its efficacy in treating moderate to severe acne, has not previously been available as a topical treatment due to its instability in traditional topical formulations. With the development of AMZEEQ, Foamix has leveraged its proprietary Molecule Stabilizing Technology (MST™) platform to conveniently and effectively deliver minocycline in a foam-based vehicle that maintains the stability of the active ingredient while delivering it directly on the skin.
https://newsfilter.io/a/6433f9616910334b89551e6cd7f1f2a4
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM